Fibroblast growth factor 19 entry into brain
Tóm tắt
Fibroblast growth factor (FGF)-19, an endocrine FGF protein mainly produced by the ileum, stimulates metabolic activity and alleviates obesity. FGF19 modulates metabolism after either intravenous or intracerebroventricular injection, and its receptor FGFR4 is present in the hypothalamus. This led to the question whether blood-borne FGF19 crosses the blood-brain barrier (BBB) to exert its metabolic effects. We determined the pharmacokinetics of FGF19 permeation from blood to brain in comparison with its distribution in peripheral organs. Multiple-time regression analysis after intravenous bolus injection, in-situ brain perfusion, and HPLC assays were performed. FGF19 was relatively stable in blood and in the brain compartment. Significant influx was seen in the presence of excess unlabeled FGF19 in blood. This coincided with a slower decline of 125I-FGF19 in blood which suggested there was decreased clearance or peripheral tissue uptake. In support of an altered pattern of peripheral processing of 125I-FGF19 by excess unlabeled FGF19, the high influx to liver was significantly attenuated, whereas the minimal renal uptake was linearly accelerated. In the present setting, we did not detect a saturable transport of FGF19 across the BBB, as the entry rate of 125I-FGF19 was not altered by excess unlabeled FGF19 or its mouse homologue FGF15 during in-situ brain perfusion. FGF19 remained stable in the blood and brain compartments for up to 10 min. Its influx to the brain was non-linear, non-saturable, and affected by its blood concentration and distribution in peripheral organs. Liver showed a robust and specific uptake of FGF19 that could be inhibited by the presence of excess unlabeled FGF19, whereas kidney clearance was dose-dependent.
Tài liệu tham khảo
Fukumoto S: Actions and mode of actions of FGF19 subfamily members. Endocr J. 2008, 55: 23-31. 10.1507/endocrj.KR07E-002.
Jones S: Mini-review: endocrine actions of fibroblast growth factor 19. Mol Pharm. 2008, 5: 42-48. 10.1021/mp700105z.
Tomlinson E, Fu L, John L, Hultgren B, Huang X, Renz M, Stephan JP, Tsai SP, Powell-Braxton L, French D, Stewart TA: Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology. 2002, 143: 1741-1747. 10.1210/en.143.5.1741.
Fu L, John LM, Adams SH, Yu XX, Tomlinson E, Renz M, Williams PM, Soriano R, Corpuz R, Moffat B, Vandlen R, Simmons L, Foster J, Stephan JP, Tsai SP, Stewart TA: Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology. 2004, 145: 2594-2603. 10.1210/en.2003-1671.
McWhirter JR, Goulding M, Weiner JA, Chun J, Murre C: A novel fibroblast growth factor gene expressed in the developing nervous system is a downstream target of the chimeric homeodomain oncoprotein E2A-Pbx1. Development. 1997, 124: 3221-3232.
Ryan KK, Kohli R, Gutierrez-Aguilar R, Gaitonde SG, Woods SC, Seeley RJ: Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology. 2013, 154: 9-15. 10.1210/en.2012-1891.
Miyake A, Itoh N: Rat fibroblast growth factor receptor-4 mRNA in the brain is preferentially expressed in cholinergic neurons in the medial habenular nucleus. Neurosci Lett. 1996, 203: 101-104. 10.1016/0304-3940(95)12272-9.
Wang QP, Guan JL, Pan W, Kastin AJ, Shioda S: A diffusion barrier between the area postrema and nucleus tractus solitarius. Neurochem Res. 2008, 33: 2035-2043. 10.1007/s11064-008-9676-y.
Peruzzo B, Pastor FE, Blazquez JL, Schobitz K, Pelaez B, Amat P, Rodriguez EM: A second look at the barriers of the medial basal hypothalamus. Exp Brain Res. 2000, 132: 10-26. 10.1007/s002219900289.
Blazquez JL, Rodriguez EM: The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides. 2010, 31: 757-776. 10.1016/j.peptides.2010.01.003.
Kastin AJ, Pan W: Blood–brain barrier and feeding: regulatory roles of saturable transport systems for ingestive peptides. Curr Pharm Des. 2008, 14: 1615-1619. 10.2174/138161208784705423.
Pan W, Kastin AJ: Interactions of cytokines with the blood–brain barrier: implications for feeding. Curr Pharm Des. 2003, 9: 827-831. 10.2174/1381612033455332.
Deguchi Y, Naito T, Yuge T, Furukawa A, Yamada S, Pardridge WM, Kimura R: Blood–brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm Res. 2000, 17: 63-69. 10.1023/A:1007570509232.
Hsuchou H, Pan W, Kastin AJ: The fasting polypeptide FGF21 can enter brain from blood. Peptides. 2007, 28: 2382-2386. 10.1016/j.peptides.2007.10.007.
Gerhard GS, Styer AM, Wood GC, Roesch SL, Petrick AT, Gabrielsen J, Strodel WE, Still CD, Argyropoulos G: A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2013, 36: 1859-1864. 10.2337/dc12-2255.
Takasato Y, Rapoport SI, Smith QR: An in situ brain perfusion technique to study cerebrovascular transport in the rat. Am J Physiol. 1984, 247: H484-H493.
Pan W, Banks WA, Kastin AJ: Permeability of the blood–brain barrier to neurotrophins. Brain Res. 1998, 788: 87-94. 10.1016/S0006-8993(97)01525-4.
Kastin AJ, Akerstrom V, Pan W: Validity of multiple-time regression analysis in measurement of tritiated and iodinated leptin crossing the blood–brain barrier: meaningful controls. Peptides. 2001, 22: 2127-2136. 10.1016/S0196-9781(01)00569-1.
Spranger J, Verma S, Gohring I, Bobbert T, Seifert J, Sindler AL, Pfeiffer A, Hileman SM, Tschop M, Banks WA: Adiponectin does not cross the blood–brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes. 2006, 55: 141-147. 10.2337/diabetes.55.01.06.db05-1077.
Kir S, Kliewer SA, Mangelsdorf DJ: Roles of FGF19 in liver metabolism. Cold Spring Harb Symp Quant Biol. 2011, 76: 139-144. 10.1101/sqb.2011.76.010710.
Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ: FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science. 2011, 331: 1621-1624. 10.1126/science.1198363.
Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, Hawkins N, Shen W, Lindberg R, Chen JL, Tian H, Li Y: C-terminal tail of FGF19 determines its specificity toward Klotho co-receptors. J Biol Chem. 2008, 283: 33304-33309. 10.1074/jbc.M803319200.
Kurosu H, Kuro O: The Klotho gene family as a regulator of endocrine fibroblast growth factors. Mol Cell Endocrinol. 2009, 299: 72-78. 10.1016/j.mce.2008.10.052.
Kuro-o M: Endocrine FGFs and Klothos: emerging concepts. Trends Endocrinol Metab. 2008, 19: 239-245. 10.1016/j.tem.2008.06.002.
Wang Y, Sun Z: Current understanding of klotho. Ageing Res Rev. 2009, 8: 43-51. 10.1016/j.arr.2008.10.002.
Reiche M, Bachmann A, Lossner U, Bluher M, Stumvoll M, Fasshauer M: Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res. 2010, 42: 178-181. 10.1055/s-0029-1243249.
Potthoff MJ, Kliewer SA, Mangelsdorf DJ: Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev. 2012, 26: 312-324. 10.1101/gad.184788.111.
Shusta EV, Boado RJ, Mathern GW, Pardridge WM: Vascular genomics of the human brain. J Cereb Blood Flow Metab. 2002, 22: 245-252.
Nishimura T, Utsunomiya Y, Hoshikawa M, Ohuchi H, Itoh N: Structure and expression of a novel human FGF, FGF-19, expressed in the fetal brain. Biochim Biophys Acta. 1999, 1444: 148-151. 10.1016/S0167-4781(98)00255-3.